Advertisement

Microglial Activation and Response to Anti-inflammatory Treatment in Major Depressive Disorder: Another Piece in the Inflammation–Mood Disorders Puzzle

      There is good news and bad news when it comes to our understanding of inflammation in the pathogenesis and treatment of major depressive disorder (MDD). The bad news is that, like the dexamethasone suppression test or the efficacy of antidepressants before it, inflammation is oversold as an answer to the mystery of depression and its treatment. The good news is that an unusually replicable set of findings (for psychiatry) increasingly paints a consistent picture of the ways in which inflammation is of value in understanding MDD. In the current issue of Biological Psychiatry, Attwells et al. (
      • Attwells S.
      • Setiawan E.
      • Rusjan P.M.
      • Xu C.
      • Hutton C.
      • Rafiei D.
      • et al.
      Translocator protein distribution volume predicts reduction of symptoms during open-label trial of celecoxib in major depressive disorder.
      ) simultaneously extend and confirm what we know already about how brain and body work together when it comes to inflammation and its role in MDD.
      SEE CORRESPONDING ARTICLE ON PAGE 649
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Attwells S.
        • Setiawan E.
        • Rusjan P.M.
        • Xu C.
        • Hutton C.
        • Rafiei D.
        • et al.
        Translocator protein distribution volume predicts reduction of symptoms during open-label trial of celecoxib in major depressive disorder.
        Biol Psychiatry. 2020; 88: 649-656
        • Felger J.C.
        Role of inflammation in depression and treatment implications.
        Handb Exp Pharmacol. 2019; 250: 255-286
        • Bai S.
        • Guo W.
        • Feng Y.
        • Deng H.
        • Li G.
        • Nie H.
        • et al.
        Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials.
        J Neurol Neurosurg Psychiatry. 2020; 91: 21-32
        • Berk M.
        • Woods R.L.
        • Nelson M.R.
        • Shah R.C.
        • Reid C.M.
        • Storey E.
        • et al.
        Effect of aspirin vs placebo on the prevention of depression in older people: A randomized clinical trial.
        JAMA Psychiatry Jun 3. 2020; : e201214
        • Raison C.L.
        • Rutherford R.E.
        • Woolwine B.J.
        • Shuo C.
        • Schettler P.
        • Drake D.F.
        • et al.
        A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers.
        JAMA Psychiatry. 2013; 70: 31-41
        • McIntyre R.S.
        • Subramaniapillai M.
        • Lee Y.
        • Pan Z.
        • Carmona N.E.
        • Shekotikhina M.
        • et al.
        Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: A randomized clinical trial.
        JAMA Psychiatry. 2019; 76: 783-790
        • Raison C.L.
        • Knight J.M.
        • Pariante C.
        Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health).
        Brain Behav Immun. 2018; 73: 1-2
        • Rapaport M.H.
        • Nierenberg A.A.
        • Schettler P.J.
        • Kinkead B.
        • Cardoos A.
        • Walker R.
        • et al.
        Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: A proof-of-concept study.
        Mol Psychiatry. 2016; 21: 71-79
        • Savitz J.B.
        • Teague T.K.
        • Misaki M.
        • Macaluso M.
        • Wurfel B.E.
        • Meyer M.
        • et al.
        Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2x2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
        Transl Psychiatry. 2018; 8: 27
        • Kappelmann N.
        • Lewis G.
        • Dantzer R.
        • Jones P.B.
        • Khandaker G.M.
        Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.
        Mol Psychiatry. 2018; 23: 335-343

      Linked Article